859537-27-2

Basic information

• Product Name: tert-Butyl (3-fluoro-4-hydroxyphenyl)carbamate
• Synonyms: tert-Butyl (3-fluoro-4-hydroxyphenyl)carbamate
• CAS NO: 859537-27-2
• Molecular Formula: C₁₁H₁₄FNO₃
• Molecular Weight: 227.2321632
• Mol File: 859537-27-2.mol

Chemical Properties

• Boiling Point: 271.365°C at 760 mmHg
• Flash Point: 117.917°C
• Appearance: /
• Density: 1.255g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.554
• CAS DataBase Reference: tert-Butyl (3-fluoro-4-hydroxyphenyl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl (3-fluoro-4-hydroxyphenyl)carbamate(859537-27-2)
• EPA Substance Registry System: tert-Butyl (3-fluoro-4-hydroxyphenyl)carbamate(859537-27-2)

Safety Data

• Hazardous Substances Data: 859537-27-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H14FNO3/c1-11(2,3)16-10(15)13-7-4-5-9(14)8(12)6-7/h4-6,14H,1-3H3,(H,13,15)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 403-19-0 2-fluoro-4-nitrophenol 

Downstream Products

• 1221714-49-3 3-fluoro-4-[2-phenyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrrolo[2,3-b]pyridin-4-yloxy]-phenyl-carbamic acid t-butyl ester 
• 1195778-98-3 N-[4-({2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}oxy)-3-fluorophenyl]-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 
• 1195778-97-2 N-[4-({2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}oxy)-3-fluorophenyl]-N'-phenylcyclopropane-1,1-dicarboxamide 
• 1195778-95-0 tert-butyl [4-({2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-b]pyridin-5-yl}oxy)-3-fluorophenyl]carbamate 
• 1195781-45-3 tert-butyl {4-[(2-amino[1,3]thiazolo[5,4-b]pyridin-5-yl)oxy]-3-fluorophenyl}carbamate 
• 1195781-47-5 N-[5-(4-amino-2-fluorophenoxy)[1,3]thiazolo[5,4-b]pyridin-2-yl]cyclopropanecarboxamide 
• 1195781-43-1 tert-butyl {3-fluoro-4-[(5-aminopyridin-2-yl)oxy]phenyl}carbamate 
• 1437323-96-0 C₂₁H₂₁FN₂O₄ 
• 1195781-41-9 tert-butyl {3-fluoro-4-[(5-nitropyridin-2-yl)oxy]phenyl}carbamate 
• 1033263-78-3 [4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluorophenyl]-carbamic acid tert-butyl ester 
• 859537-30-7 tert-butyl (3-fluoro-4-(6-methanesulfonyl-pyridin-3-yloxy)-phenyl)-carbamate 
• 911297-14-8 (S)-3-(4-amino-2-fluorophenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenylcarbamoyl)propionamide 
• 911297-10-4 (S)-{3-fluoro-4-[2-hydroxy-2-(4-nitro-3-trifluoromethylphenylcarbamoyl)propoxy]phenyl}carbamic acid tert-butyl ester 

Relevant articles and documents

PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.

NPY ANTAGONISTS, PREPARATION AND USES

The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.

NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE

A glucokinase activator is provided; and a remedy and/or a preventive for diabetes, or a remedy and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a remedy and/or a preventive f

Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer

A new series of androgen receptor targeted agents (ARTA) was prepared and tested in androgen-dependent and -independent prostate cancer cell lines. These agents were bicalutamide analogs with isothiocyanato substituted B-rings. Also, the linker sulfone of R-bicalutamide was maintained or replaced with several alternative linkages including ether, amine, N-methylamine, thioether, and methylene (in this case the product was a racemic mixture) functional groups at the X-position. To expand the structure-activity relationship (SAR) of these arylisothiocyanato AR ligands, B-ring halogenated arylisothiocyanato ligands were also prepared and tested. The arylisothiocyanato AR ligands showed strong binding affinities to AR ranging from 0.6 to 54 nM. Among them, thioether and ether linkages demonstrated high binding affinities (0.6 and 4.6 nM, respectively) and selective cell growth inhibition (approximately 3- to 6-fold) for LNCaP, an androgen-dependent prostate cancer cell line, when compared to the androgen independent prostate cell lines (DU145, PC-3, and PPC-1) and a bladder cell line (TSU-Pr1). However, the ligands were inactive (IC50>100 mM) in a normal monkey kidney cell line (CV-1) that was used as the control for non-specific toxicity.